The successful patient-preference design for the LORD-trial to test whether active surveillance for low-risk Ductal Carcinoma In Situ is safe

Renée Schmitz(The Netherlands Cancer Institute), J. Wesseling(The Netherlands Cancer Institute), Vincent van der Noort(Dutch Cancer Society), R. Mann(Dutch Cancer Society), M. van Oirsouw(Borstkankervereniging Nederland), E. Bleiker(The Netherlands Cancer Institute), N. Bijker(Amsterdam University Medical Centers), Miranda Gerritsma(The Netherlands Cancer Institute), E. Engelhardt(Dutch Cancer Society), Frederieke van Duijnhoven(The Netherlands Cancer Institute), C. Sondermeijer(The Netherlands Cancer Institute), E. Verschuur(Borstkankervereniging Nederland)
European Journal of Cancer
November 1, 2022
10.1016/s0959-8049(22)01355-7
Cited by 0

Related Papers

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study
|BMJ|2023|44
Active surveillance versus treatment in low-risk DCIS: Women’s preferences in the LORD-trial
|European Journal of Cancer|2023|39
Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
|Cancers|2021|18
Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review
|Cancers|2022|15
Supporting Patients With Incurable Cancer: Backup Behavior in Multidisciplinary Cross-Functional Teams
|Journal of Oncology Practice|2016|11